{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:14:01Z","timestamp":1777580041794,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2003,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of 0.2% brimonidine eye drops given twice daily in normal tension glaucoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Sixteen consecutive patients fulfilling eligibility criteria (glaucomatous optic neuropathy associated with visual field defect in at least one eye, intraocular pressure (IOP) = 18 mmHg (average of the two highest readings of the round-the-clock curve, including one reading at midnight in supine position), no prior glaucoma therapy, angle wide open, visual acuity 20\/40 or better) were enrolled in this prospective, randomized, placebo-controlled clinical trial with crossover design, lasting 30 days for each treatment phase plus 15-day washout in between. Main outcome was IOP (average of the two highest readings of the round-the-clock curve).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean IOP was significantly reduced by brimonidine (from 17.1 \u00b1 0.7 mm Hg to 13.9 \u00b1 2.2 mmHg, p&lt;0.001 (paired Student t-test)). At the end of the 30-day brimonidine phase, 4 of 16 subjects showed a \u226530% IOP decrease over baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the short term, 0.2% brimonidine eye drops can induce a significant IOP decrease in eyes with normal tension glaucoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/112067210301300703","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:32:58Z","timestamp":1516321978000},"page":"611-615","source":"Crossref","is-referenced-by-count":10,"title":["Effect of Brimonidine on Intraocular Pressure in Normal Tension Glaucoma: A Short Term Clinical Trial"],"prefix":"10.1177","volume":"13","author":[{"given":"S.A.","family":"Gandolfi","sequence":"first","affiliation":[{"name":"Glaucoma Research and Care Center, University of Parma, Parma - Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cimino","sequence":"additional","affiliation":[{"name":"Glaucoma Research and Care Center, University of Parma, Parma - Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mora","sequence":"additional","affiliation":[{"name":"Glaucoma Research and Care Center, University of Parma, Parma - Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,8,1]]},"reference":[{"key":"bibr1-112067210301300703","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(97)30172-9"},{"key":"bibr2-112067210301300703","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00223-2"},{"key":"bibr3-112067210301300703","first-page":"847","volume":"114","author":"Schuman J.S.","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"bibr4-112067210301300703","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)91048-X"},{"key":"bibr5-112067210301300703","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)87981-3"},{"key":"bibr6-112067210301300703","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)00076-8"},{"key":"bibr7-112067210301300703","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(97)80013-6"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210301300703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210301300703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:39:26Z","timestamp":1777405166000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/112067210301300703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":7,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["10.1177\/112067210301300703"],"URL":"https:\/\/doi.org\/10.1177\/112067210301300703","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}